Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tegafur + pirarubicin + ifosfamide
- Development stage
- Unknown
- Lead developer
- Taiho Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Tegafur + pirarubicin + ifosfamide is a combination chemotherapy regimen, sometimes referred to as "CAF," used primarily in the treatment of breast cancer. Tegafur is a prodrug of fluorouracil (5-FU), which acts as an antimetabolite by inhibiting thymidylate synthase and thereby interfering with DNA synthesis[5]. Pirarubicin is an anthracycline antibiotic that intercalates into DNA and inhibits topoisomerase II, leading to DNA strand breaks. Ifosfamide is an alkylating agent that forms DNA crosslinks, inhibiting protein and DNA synthesis[2][6]. This combination targets rapidly dividing cancer cells through multiple mechanisms affecting nucleic acid function and integrity. The regimen has been studied for its effects on reproductive health in women with breast cancer[8].
- Other names
- CAF
02
Targets
TS (Thymidylate synthase)DNATOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on tegafur + pirarubicin + ifosfamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tegafur + pirarubicin + ifosfamide.